Gene Therapies for Rare Diseases

Gene therapies are redefining what’s possible in rare disease treatment.

In our latest whitepaper, Ergomed experts examine how advances in gene editing platforms, delivery modalities, and vector systems are transforming the development of therapies for rare diseases. With most rare diseases rooted in genetic causes—and 95% lacking approved treatments—the opportunity to move beyond symptom management toward long-lasting or curative solutions has never been greater. Drawing on real-world approvals and pipeline innovations, this guide explores how technologies like CRISPR, base editing, and prime editing, combined with smarter delivery and vehicle strategies, are unlocking new treatment pathways. Download our whitepaper to learn how cutting-edge science, combined with strategic development expertise, is accelerating the future of precision medicine—for the benefit of both patients and sponsors.